Suggestions
Alexander Varond
FDA Partner & FDA Litigation Co-Chair, Goodwin Life Sciences
Alexander Varond is a prominent figure in the field of FDA regulatory law and litigation. He serves as a Partner at Goodwin and holds the position of Co-Chair of the firm's FDA Litigation practice.1 His expertise spans across various aspects of the life sciences and technology sectors, with a particular focus on advising clients in the pharmaceutical, biotechnology, and medical device industries.1
Professional Background
Alexander's career is characterized by a unique blend of technical and legal expertise:
- Current Role: Partner in Goodwin's Technology and Life Sciences groups and Co-Chair of the FDA Litigation practice1
- Previous Experience: Senior Associate at Hyman, Phelps & McNamara, PC before joining Goodwin in 20171
- Industry Experience: Worked as a medical device engineer, operations manager, and deputy management representative to the FDA1
Areas of Expertise
Alexander's practice covers a wide range of FDA regulatory matters, including:
- Drug and medical device development
- Hatch-Waxman patent and exclusivity issues
- Regulatory strategy
- Advertising and promotional issues
- Civil and criminal investigations
- Corporate transactions1
Recognition and Achievements
Alexander has received numerous accolades for his work:
- Named a Top Healthcare Lawyer by the Daily Journal in 20233
- Recognized in The Best Lawyers in America for FDA Law (2022-2023)
- Listed as a "Rising Star" in Food & Drug Law by Super Lawyers (2019-2023)
- Acknowledged as a "Next Generation Partner" in Healthcare: Life Sciences by The Legal 500 United States (2022-2023)1
Education and Bar Admissions
- Education: J.D. from The George Washington University Law School; B.S. in Biomedical Engineering and Management Science from the University of California, San Diego1
- Bar Admissions: District of Columbia and California1
Alexander Varond's LinkedIn username is indeed avarond, as mentioned in the query.2
Highlights
I'm incredibly excited to continue making a splash in California healthcare and life sciences, this time being named a Top Healthcare Lawyer by Daily Journal Corporation! The West Coast is an important, vibrant, and rapidly growing market--and it's also pretty unique. It's a true honor to be a part of the team at Goodwin working with these talented folks to drive innovation and patient-focused care.
FDA just made public its Lumryz letter decision on orphan drug exclusivity and clinical superiority. Worth a read for anyone in the orphan/Hatch Waxman space, especially for its in-depth discussion of major contribution to patient care (MCTPC). For example:
"Nonetheless, FDA has concluded that Lumryz is clinically superior to Xywav as a MCTPC given the benefit of Lumryz’s once-nightly dosing despite Xywav’s greater safety due to reduced sodium. First, as explained above, there is no requirement for comparable safety when making a MCTPC finding, and finding clinical superiority based on one parameter — greater safety, greater efficacy, or a MCTPC — is sufficient to meet the clinical superiority standard."
"FDA does not require direct comparative clinical trials to demonstrate that a drug makes a MCTPC."
https://lnkd.in/g_dgWqqV #fda
